Close Menu

NEW YORK – BioMérieux on Wednesday reported sales growth of 16 percent for the first half of 2020 compared to the first half of 2019.

The French diagnostics firm reported total sales of €1.48 billion ($1.75 billion) for the six-month period ended June 30, 2020, up from €1.28 billion for the first half of 2019.

For the first half of the year, its clinical applications sales were up 19 percent at €1.26 billion versus €1.06 billion for the first half of 2019. The firm's industrial applications had sales of €218.8 million, a slight increase from €218.3 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

President Donald Trump might not approve the stricter standards the US Food and Drug Administration is developing for authorizing a SARS-CoV-2 vaccine, according to Politico.

Wired reports that Oxitec has now developed a genetically modified fall armyworm.

A large genetic study finds SARS-CoV-2 viruses with a certain variant are spreading more than others, according to the Washington Post.

In Nature this week: sister-chromatid-sensitive chromosome conformation capture approach, and more.